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In search of alternatives to antimicrobial agents currently in use, 
and in order to respond to the landscape of loss of efficacy due to the 
emergence of resistance, several research groups are evaluating several 
familiesof compounds, among them the quinoxaline derivatives family, 
which presented several other potential biological applications.
Quinoxaline derivatives are an important class of heterocyclic 
compounds, where N replaces some carbon atoms in the ring. 
Quinoxaline molecular formula is C8H6N2 and is formed by two 
aromatic rings, benzene and pyrazine. It is rare in natural state, but 
their synthesis is easy to perform [1]. Modifying its structure is possible 
to obtain a wide variety of compounds with different biological 
properties.
In the last two decades, several quinoxaline derivatives have been 
tested and presented antimicrobial activity, as antifungal [2-4] and 
antibacterial agents [2-13]. The antibacterial activity observed covers 
both Gram-negative and Gram-positive bacteria [6,8,11-13], including 
Mycobacterium species [4,7,9,10,14,15]. There are also data pointing 
to activity against multidrug resistant Mycobacterium tuberculosis 
[15]. Several studies have been described, concerning synthesis and 
biological activity of a large amount of quinoxalines. Some quinoxaline 
1,4-di-N-oxide derivatives have been shown to inhibit M. tuberculosis 
to a rate of 99 to 100% [9,16].
Antifungal activity for quinoxaline derivatives has been tested 
against Candida albicans [17,18]. Thieno[2,3-d]-pyrimidines and 
pyrrolo[3,4-b]-quinoxalines  were among the synthesized compounds 
that presented this kind of biological activity. Researchers also reported 
some 2-sulphonyl quinoxalines and 3-[(alkylthio) methyl] quinoxaline-
1-oxide derivatives as compounds with high antifungal activity [4], and 
also pyrazolo quinoxalines which were observed to be active against
fungal infections [19].
There are quinoxaline derivatives that present anti-protozoan 
activity [20,21], especially anti-amoebic [22-24], against Plasmodium 
and Leishmania species (strain MHOM/BR/76/LTB-012A) [21,25]. 
Compounds with one halogenous group in position 6 and 7 of the 
quinoxaline core provide an efficient approach for further development 
of antimalarial and antileishmanial agent [21].
Quinoxaline derivatives present other biological properties.  Anti-
cancer activity has been already studied [26-28], and results obtained 
are very promising. Recently, our research group has demonstrated 
anti-proliferative activity in several cancer cell lines. 
Antioxidant and anti-inflammatory activity has also been explored 
for quinoxaline derivatives [29-31]. Some compounds presented anti-
inflammatory effect similar to the reference drug used, indomethacin 
[29]. 
Some cooper and zinc quinoxaline derivative complexes have 
presented antidiabetic activity [32] and N-arylcarbamoyl and N-aryl 
thiocarbamoyl derivatives revealed hypoglycemic behavior in Wister 
rats. 
Quinoxaline-5,8-diones derivatives were tested for their inhibitory 
activity on rat aortic smooth muscle cell proliferation and results 
revealed good proliferation inhibition.Thus the quinoxaline-5,8-diones 
were found as promising anti-atherosclerotic agents [16,19,33].
New series of structurally novel 3-substituted-2-carboxamides 
quinoxaline exhibited 5-HT3 (serotonin) receptor antagonism, and 
some of them showed antagonism greater than the standard TCA 
(Tricyclic anti-depressant) drugs [34].
A series of 7-heterocycle-substituted quinoxaline carboxylic acids 
were tested for their neuroprotective efficacy. One of the synthesized 
compounds was found to possess high neuroprotective effect in vitro 
and showed excellent in vivo activity [35].
Due to the wide range of applications, quinoxaline derivative 
compounds have aroused the interest of the scientific community, 
especially in the last decade. Given the ability to design different 
structures from the quinoxaline core, improvement of biological 
activities may be achieved, as well as new applications.
References
1. Loriga M, Vitale G, Paglietti G (1998) Quinoxaline chemistry - Part 9. Quinoxaline 
analogues of trimetrexate (TMQ) and 10-propargyl-5,8-dideazafolic acid
(CB 3717) and its precursors. Synthesis and evaluation of in vitro anticancer 
activity. Farmaco 53: 139-149.
2. Tandon VK, Yadav DB, Maurya HK, Chaturvedi AK, Shukla PK (2006) Design, 
synthesis, and biological evaluation of 1,2,3-trisubstituted-1,4-dihydrobenzo[g]
quinoxaline-5,10-diones and related compounds as antifungal and antibacterial 
agents. Bioorg Med Chem 14: 6120-6126.
3. Kalinin AA, Voloshina AD, Kulik NV, Zobov VV, Mamedov VA (2013)
Antimicrobial activity of imidazo[1,5-a]quinoxaline derivatives with pyridinium
moiety. Eur J Med Chem 66: 345-354.
4. Carta A, Paglietti G, Rahbar Nikookar ME, Sanna P, Sechi L, et al. (2002)
Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and
anti-candida activity. Eur J Med Chem 37: 355-366.
5. Sanna P, Carta A, Loriga M, Zanetti S, Sechi L (1999) Preparation and
biological evaluation of 6/7-trifluoromethyl(nitro)-, 6,7-difluoro-3-alkyl (aryl)-
substituted-quinoxalin-2-ones. Part 3. Farmaco 54: 169-177.
6. Khan SA, Saleem K, Khan Z (2007) Synthesis, characterization an in vitro
antibacterial activity of new steroidal thiazolo quinoxalines. Eur J Med Chem
42: 103-108.
7. Ramalingam P, Ganapaty S, Rao ChB (2010) In vitro antitubercular and
antimicrobial activities of 1-substituted quinoxaline-2,3(1H,4H)-diones. Bioorg











Biochemistry & Pharmacology: Open
Access
Citation: Vieira M, Ferraz R, Fernandes R, Prudêncio C (2014) New Quinoxalines with Biological Applications. Biochem Pharmacol 3: e152. 
doi:10.4172/2167-0501.1000e152
Page 2 of 2
Volume 3 • Issue 1 • 1000e152
Biochem Pharmacol
ISSN:2167-0501 BCPC, an open access journal 
8. Ishikawa H, Sugiyama T, Kurita K, Yokoyama A (2012) Synthesis and
antimicrobial activity of 2,3-bis(bromomethyl)quinoxaline derivatives. Bio org
Chem 41-42: 1-5.
9. Jaso A, Zarranz B, Aldana I, Monge A (2003) Synthesis of new 2-acetyl and
2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti-Mycobacterium
tuberculosis agents. Eur J Med Chem 38: 791-800.
10. Vicente E, Villar R, Burguete A, Solano B, Pérez-Silanes S, et al. (2008)
Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental 
tuberculosis. Antimicrob Agents Chemother 52: 3321-3326.
11. Segreti J, Goodman LJ, Trenholme GM (1993) in-vitro activity of new
quinoxaline compounds against campylobacter species and clostridium-
difficile. Diagn Microbiol Infect Dis 17: 177-179.
12. Khan SA, AsiriAM (2011) Synthesis of novel steroidal oxazoloquinoxaline as
antibacterial agents. Arabian Journal of Chemistry 4: 349-354.
13. Vieira M, Pinheiro C2, Fernandes R3, Noronha JP4, Prudêncio C5 (2013)
Antimicrobial activity of quinoxaline 1,4-dioxide with 2- and 3-substituted
derivatives. Microbiol Res .
14. Zanetti S, Sechi LA, Molicotti P, Cannas S, Bua A, et al. (2005) In vitro activity 
of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium 
tuberculosis and other mycobacteria. Int J Antimicrob Agents 25: 179-181.
15. Antonio Carta, Michele Palomba, Giuseppe Paglietti, Paola Molicotti, Bianca
Paglietti, et al. (2007) [1,2,3]Triazolo[4,5-h]quinolones. A new class of potent
antitubercular agents against multidrug resistant Mycobacterium tuberculosis
strains. Bioorg Med ChemLett17: 4791-4794.
16. Asif Husain, Diwakar Madhesia (2011) Recent advances in pharmacological
activities of quinoxalinederivates. Journal of pharmacy research 4: 924-929.
17. Patidar A, Jeyakandan M, Mobiya A, Selvam G (2011) Exploring potential of
quinoxaline moiety. International Journal of Pharm Tech Research 3: 386-392.
18. Ammar YA, Ismail MMF,  El-Gaby MSA, Zahran MA (2002) Some reactions with 
quinoxaline-2,3-dicarboxylic acid anhydride: Novel synthesis of thieno[2,3-d]
pyrimidines and pyrrolo[3,4-b]quinoxalines as antimicrobial agents. Indian
Journal of Chemistry 41B: 1486-1491.
19. Deepika Y., N.P., Sachin K., Shewta S., Biological activity of quinoxaline
derivatives. International Journal of Current Pharmaceutical Review and
Research, 2011. 1(3): p. 33-46.
20. Torres E, Moreno-Viguri E, Galiano S, Devarapally G, Crawford PW, et
al. (2013) Novel quinoxaline 1,4-di-N-oxide derivatives as new potential
antichagasic agents. Eur J Med Chem 66: 324-334.
21. Barea C, Pabón A, Castillo D, Zimic M, Quiliano M (2011) New salicylamide
and sulfonamide derivatives of quinoxaline 1,4-di-N-oxide with antileishmanial
and antimalarial activities. Bio org Med Chem Lett 21: 4498-4502.
22. Budakoti A, Bhat AR, Azam A (2009) Synthesis of new 2-(5-substituted-
3-phenyl-2-pyrazolinyl)-1,3-thiazolino[5,4-b]quinoxaline derivatives and
evaluation of their antiamoebic activity. Eur J Med Chem 44: 1317-1325.
23. Abid M, Azam A (2006) Synthesis, characterization and antiamoebic activity
of 1-(thiazolo[4,5-b]quinoxaline-2-yl)-3-phenyl-2-pyrazoline derivatives. Bioorg
Med Chem Lett 16: 2812-2816.
24. Duque-Montaño BE, Gómez-Caro LC, Sanchez-Sanchez M, Monge A,
Hernández-Baltazar E, et al. (2013) Synthesis and in vitro evaluation of new
ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide against Entamoeba
histolytica. Bioorg Med Chem 21: 4550-4558.
25. Barea C, Pabón A, Galiano S, Pérez-Silanes S, Gonzalez G, et al. (2012) Anti-
plasmodial and leishmanicidal activities of 2-cyano-3-(4-phenylpiperazine-1-
carboxamido) quinoxaline 1,4-dioxide derivatives. Molecules 17: 9451-9461.
26. Piras S, Loriga M, Paglietti G (2004) Quinoxaline chemistry. Part XVII. Methyl
4-(substituted 2-quinoxalinyloxy) phenyl acetates and ethyl N-( 4-(substituted
2-quinoxalinyloxy) phenyl acetyl) glutamates analogs of methotrexate:
synthesis and evaluation of in vitro anticancer activity. Farmaco 59: 185-194.
27. Galal, S.A.Galal SA, Abdelsamie AS, Soliman SM, Mortier J, Wolber G, et al.
(2013) Design, synthesis and structure–activity relationship of novel quinoxaline 
derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase
receptor. European Journal of Medicinal Chemistry 69: 115-124.
28. Ingle R, Marathe R, Magar D, Patel HM, Surana SJ (2013) Sulphonamido-
quinoxalines: search for anticancer agent. Eur J Med Chem 65: 168-186.
29. Asunción Burguete, Eleni Pontiki, Dimitra Hadjipavlou-Litina, SaioaAncizu,
Raquel Villar, et al. (2011) Synthesis and Biological evaluation of New
Quinoxaline Derivatives as Antioxidant and Anti-Inflammatory Agents. 
ChemBiol Drug Des 77: 255-267.
30. Torres E, Moreno E, Ancizu S, Barea C, Galiano S (2011) New 1,4-di-N-oxide-
quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-
Mycobacterium tuberculosis agents. Bioorg Med ChemLett21: 3699-3703.
31. Abu-Hashem AA, Gouda MA, Badria FA (2010) Synthesis of some new
pyrimido [2',1':2,3]thiazolo[4,5-b]quinoxaline derivatives as anti-inflammatory 
and analgesic agents. Eur J Med Chem 45: 1976-1981.
32. Naveen V Kulkarni, Vidyanand K Revankar, Kirasur BN, Mallinath H Hugar
(2012) Transition metal complexes of thiosemi carbazones with quinoxaline
hub: an emphasis on antidiabetic property. Medicinal Chemistry Research 21:
663-671.
33. Chung HJ, Jung OJ, Chae MJ, Hong SY, Chung KH, et al. (2005) Synthesis
and biological evaluation of quinoxaline-5,8-diones that inhibit vascular smooth 
muscle cell proliferation. Bio org Med Chem Lett 15: 3380-3384.
34. Mahesh R, Devadoss T, Pandey DK, Bhatt S (2011) Discovery of new
anti-depressants from structurally novel 5-HT3 receptor antagonists:
design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-
carboxamides. Bio org Med Chem Lett 21: 1253-1256.
35. Takano Y, Shiga F, Asano J, Ando N, Uchiki H, et al. (2003) Synthesis and
AMPA receptor antagonistic activity of a novel class of quinoxaline carboxylic
acid with a substituted phenyl group at the C-7 position. Bioorg Med Chem Lett 
13: 3521-3525. 
